ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DERM vs ALXO // EV/EBITDA & P/E VALUATION

Journey Medical Corporation (NASDAQ) VS. ALX Oncology Holdings Inc. (NASDAQ) • 15-METRIC TALLY: DERM 3 — ALXO 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DERM VS. ALXO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DERM ALXO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 65.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -19.50% -35.00% +15.50 DERM /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -8.15% — — TIE /fcf-yield <GO>
Operating Margin -13.30% — — TIE /operating-margins <GO>
Net Profit Margin -18.70% — — TIE /net-margins <GO>
Revenue Growth (YoY) 11.10% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.74 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 4/9 +1.00 DERM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.5 47.4 -6.98 ALXO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $152.7M $152.4M $287.2K DERM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DERM REV ALXO REV DERM GROSS % ALXO GROSS % DERM FCF ALXO FCF
FY 2025 $61.2M $0 65.8% — -$12.4M -$84.4M
FY 2024 $55.1M $0 62.1% — -$9.1M -$122.4M
FY 2023 $59.7M $0 — — $5.2M -$130.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DERM // BETA —
ALXO // BETA —